Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate

被引：57

作者：

Kirby, B ^{[1
]}

Marsland, AM

Carmichael, AJ

Griffiths, CEM

机构：

[1] Univ Manchester, Hope Hosp, Dermatol Ctr, Salford M6 8HD, Lancs, England

[2] S Cleveland Hosp, Dept Dermatol, Middlesbrough, Cleveland, England

来源：

CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2001年 / 26卷 / 01期

关键词：

D O I：

10.1046/j.1365-2230.2001.00753.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Plaques of psoriasis contain increased levels of cytokines, including tumour necrosis factor-alpha (TNF-alpha), which are thought to be essential to the maintenance of the psoriatic process. We report the successful treatment of severe, recalcitrant psoriasis when infliximab (a monoclonal antibody to TNF-alpha) was used in combination with methotrexate.

引用

页码：27 / 29

页数：3

共 10 条

[1] The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations:: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients [J].

Austin, LM ;

Ozawa, M ;

Kikuchi, T ;

Walters, IB ;

Krueger, JG .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (05) :752-759

[2] ELEVATED TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) BIOLOGICAL-ACTIVITY IN PSORIATIC SKIN-LESIONS [J].

ETTEHADI, P ;

GREAVES, MW ;

WALLACH, D ;

ADERKA, D ;

CAMP, RDR .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1994, 96 (01) :146-151

[3] The influence of row position and selected soil attributes on Acarina and Collembola in no-till and conventional continuous corn on a clay loam soil [J].

Fox, CA ;

Fonseca, EJA ;

Miller, JJ ;

Tomlin, AD .

APPLIED SOIL ECOLOGY, 1999, 13 (01) :1-8

[4] SEVERE PSORIASIS - ORAL THERAPY WITH A NEW RETINOID [J].

FREDRIKSSON, T ;

PETTERSSON, U .

DERMATOLOGICA, 1978, 157 (04) :238-244

[5] Review article: safety of infliximab in clinical trials [J].

Hanauer, SB .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 :16-22

[6] The Salford Psoriasis Index: an holistic measure of psoriasis severity [J].

Kirby, B ;

Fortune, DG ;

Bhushan, M ;

Chalmers, RJG ;

Griffiths, CEM .

BRITISH JOURNAL OF DERMATOLOGY, 2000, 142 (04) :728-732

[7] Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial [J].

Maini, R ;

St Clair, EW ;

Breedveld, F ;

Furst, D ;

Kalden, J ;

Weisman, M ;

Smolen, J ;

Emery, P ;

Harriman, G ;

Feldmann, M ;

Lipsky, P .

LANCET, 1999, 354 (9194) :1932-1939

[8] Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial [J].

Mease, PJ ;

Goffe, BS ;

Metz, J ;

VanderStoep, A ;

Finck, B ;

Burge, DJ .

LANCET, 2000, 356 (9227) :385-390

[9] Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions [J].

Oh, CJ ;

Das, KM ;

Gottlieb, AB .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 42 (05) :829-830

[10] Introduction: anti-TNF strategies in the treatment of Crohn's disease [J].

Rutgeerts, PJ ;

Targan, SR .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 :1-1

← 1 →